PVLA Earnings

PVLA reported its earnings on 2025-11-11, showcasing a revenue of 0.00 against an estimate of 400.00K, resulting in a -100% surprise. The EPS was -1.03, surpassing the expected -0.85 by -21.18% . The stock experienced a -3.04% price change on the earnings day and a 4.27% change over the next five days, reflecting market reactions to the results.

Following PVLA's earnings announcement on 2025-11-11, the stock price moved by -3.04% on the day of the release. Over the subsequent five days, it saw a 4.27% change. Historically, PVLA's stock price tends to shift by an average of -4.13% in the 10 days leading up to earnings and +8.03% in the 10 days following, providing insight into potential market.

For , analysts estimate PVLA’s annual revenue to reach , while the EPS is projected at . These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -7.68% and EPS estimates Revise Downward by -22.23% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between PVLA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Downward by -7.68%, while EPS estimates moved Revise Downward by -22.23% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PVLA's stock price typically moves by -4.13% in the 10 days before its earnings and +8.03% in the 10 days after. For the upcoming earnings, analysts expect an EPS of and revenue of .

The earnings call presents a mixed picture: while the company has a strong cash position and a two-year runway, there are concerns about increased expenses and competitive pressures. The Q&A section reveals uncertainties in pricing strategies and infrastructure needs, which could be negative. However, alignment with the FDA on endpoints and a strong cash position are positives. The lack of guidance on pricing and potential regulatory risks balance out the positives, leading to a neutral sentiment.